Celgene’s Commitment to Myelofibrosis

Myelofibrosis is a rare bone marrow cancer and one of a related group of blood cancers known as myeloproliferative neoplasms (MPNs) in which bone marrow cells that produce the blood cells develop and function abnormally. It is characterized by splenomegaly (enlarged spleen), cytopenias, bone marrow fibrosis and debilitating symptoms including fatigue, weight loss and bone pain. Some other MPNs that can progress to myelofibrosis include polycythemia vera and essential thrombocythemia.

Building on Celgene’s unwavering commitment to patients and our history in hematologic malignancies, we are excited to be moving into the myelofibrosis area.

Advocacy & Collaboration


Celgene currently has clinical studies for patients with myelofibrosis. We remain committed to addressing the needs of patients with myelofibrosis and improving the lives of patients with this disease.